Ivonescimab delayed lung cancer progression. Why did the FDA still reject Summit’s application?
FDA rejects Summit's ivonescimab application over survival evidence. Discover what the decision means for HARMONi, investors and future trials.
FDA rejects Summit's ivonescimab application over survival evidence. Discover what the decision means for HARMONi, investors and future trials.
Akeso's ivonescimab delivered 70.1% major pathological response in resectable lung cancer. The Phase 2 trial reveals promise and limitations.
Summit Therapeutics and Lunit will study AI-derived tumor biomarkers for ivonescimab, while clinical validation and patient-selection benefits remain unproven.
Summit shares rise after ivonescimab delivers 30.8-month survival versus 22.6 months for pembrolizumab in China’s HARMONi-2 trial.
Global HARMONi data show ivonescimab plus chemotherapy reduced progression or death risk by 48% after third-generation EGFR-TKI failure, while overall survival had not reached statistical significance at the primary analysis.
Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.
Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.